In fact, in vitro studies demonstrated that regorafenib also inhibited FGFR signalling in MCF‐7 breast cancer by inhibiting phosphorylated FGFR substrate 2 (pFRS2) and the downstream signalling kinase pERK1/217. This evidence concerns the gene FRS2 and breast carcinoma.